GlassScriptPhysician profile
Shawn Marein
NPI 1265964878
$14,001.40
in general payments reported to CMS, 2019-2025
19 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $114 · 2021: $735 · 2022: $1,076 · 2023: $1,389 · 2024: $11K · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $8,669 · Travel and Lodging: $2,736 · Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $8,668.98 |
| Travel and Lodging | $2,736.48 |
| Food and Beverage | $671.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $11,253.47 | 2023-2024 | Da Vinci Surgical System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $908.37 | 2020-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $714.32 | 2021-2023 | Tezspire, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $265.42 | 2020-2024 | Trelegy Ellipta, Nucala |
| Actelion Pharmaceuticals US, INC. | $217.55 | 2023-2024 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $113.39 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $90.07 | 2023 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $89.47 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $81.99 | 2022 | |
| Insmed, INC. | $50.98 | 2022-2025 | Brinsupri, Arikayce |
| Genzyme Corporation | $48.55 | 2021-2022 | |
| Abiomed | $30.15 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.95 | 2022 | |
| Bard Peripheral Vascular, INC. | $25.11 | 2021 | |
| Mylan Specialty L.P. | $22.88 | 2023 | Yupelri |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $18.99 | 2021 | |
| Amgen INC. | $15.69 | 2022 | |
| Merck Sharp & Dohme LLC | $14.78 | 2021 | |
| Genentech USA, INC. | $14.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Marein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.